Hematology and Oncology

My clinical domain is breast cancer management. My clinical research interest focuses on the development of novel therapies for the treatment of breast cancer. Clinical trials focusing on precision medicine for defining the right therapy, for the right patient at the right time is our goal. To that end, molecular interogation of breast tumors are leading to novel trial design that will hopefully translate into better outcomes for our patients. In conjuction with the developmental therapeutics program, novel agents are being incorporated into clinical trials for patients with both early and lat...

Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Division of Hematology Oncology, Department of Medicine, and the Deputy Director at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine. She is a practicing oncologist, internationally renowned expert and clinical researcher in genitourinary oncology particularly prostate and bladder cancer. Her clinical research has contributed to impacting the standards of care for patients with metastatic hormone sensitive and castration resistant prostate cancer. Prior ...

Colon cancer, Gastric cancer, Pancreas cancer, Rectal cancer

Dr. Siziopikou's subspecialty focus is on breast tumor markers and molecular diagnostics in breast cancer. Her research interests center around molecular markers of prognostic and predictive significance in breast cancer.

Cancer immunology and immunotherapy. The Zhang laboratory functions as an integrated translational research program with the goal of designing and developing new immunotherapies and immunologic strategies for cancer treatment. The ongoing projects are focused on dissecting the molecular mechanisms used for tumor immune evasion based on the cutting-edge technical platforms.

Dr. VanderWeele did his medical and research training at the University of Chicago, where he developed a research program characterizing the heterogeneity and evolution of the cancer genome. He moved to the National Cancer Institute in Bethesda, MD, where he continued to seek to improve the treatment of prostate cancer based on patients’ specific genetic changes. He returned to Chicago in 2018 to join the GU cancer team at Northwestern University, where he continues to translate discoveries made at the bench into improved therapies in the clinic.

My primary interests are in developing novel therapeutic combinations for the treatment of gastrointestinal cancers. I am interested in incorporating immunotherapy and molecular testing into clinical trials.

My interests include treating primary brain tumors such as gliomas and meningiomas. I also have a specific interest in metastatic disease to the brain from systemic cancers such as melanoma, lung and breast cancer and lead multiple trials in both primary brain tumors and metastatic disease. I am interested in providing novel care to my patients while maintaining quality of life.

Leukemia, Lymphoma, Myeloma